Follow
Bernhard Eigl
Bernhard Eigl
Clinical Associate Professor, University of British Columbia
Verified email at bccancer.bc.ca
Title
Cited by
Cited by
Year
Early childhood development coming of age: science through the life course
MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ...
The Lancet 389 (10064), 77-90, 2017
26492017
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …
DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...
Journal of clinical oncology 27 (34), 5794-5799, 2009
22432009
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ...
The Lancet 389 (10064), 67-76, 2017
20532017
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
4452018
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
3772020
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
KN Chi, SJ Hotte, EY Yu, D Tu, BJ Eigl, I Tannock, F Saad, S North, ...
J Clin Oncol, 2009
2872009
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 …
DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ...
The Lancet Oncology 20 (12), 1730-1739, 2019
2842019
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients
AA Azad, BJ Eigl, RN Murray, C Kollmannsberger, KN Chi
European urology 67 (1), 23-29, 2015
1912015
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors
A Jimeno, GJ Weiss, WH Miller Jr, S Gettinger, BJC Eigl, ALS Chang, ...
Clinical cancer research 19 (10), 2766-2774, 2013
1892013
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
KN Chi, T Kheoh, CJ Ryan, A Molina, J Bellmunt, NJ Vogelzang, ...
Annals of Oncology 27 (3), 454-460, 2016
1522016
Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer
G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ...
Clinical cancer research 23 (21), 6487-6497, 2017
1442017
Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis
A Karsan, BJ Eigl, S Flibotte, K Gelmon, P Switzer, P Hassell, D Harrison, ...
Clinical chemistry 51 (8), 1525-1528, 2005
1252005
AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate
T Todenhöfer, A Azad, C Stewart, J Gao, BJ Eigl, ME Gleave, AM Joshua, ...
The Journal of urology 197 (1), 135-142, 2017
1232017
Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer
AI So, RJ Levitt, B Eigl, L Fazli, M Muramaki, S Leung, MCU Cheang, ...
Clinical Cancer Research 14 (21), 6944-6954, 2008
992008
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ...
Nature Communications 12 (1), 184, 2021
982021
Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer
BJC Eigl, SE Eggener, J Baybik, S Ettinger, KN Chi, C Nelson, Z Wang, ...
Clinical Cancer Research 11 (13), 4905-4911, 2005
822005
Targeting the apoptosis pathway in prostate cancer
RR Zielinski, BJ Eigl, KN Chi
The Cancer Journal 19 (1), 79-89, 2013
772013
Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II …
DJ Khalaf, K Sunderland, BJ Eigl, CK Kollmannsberger, N Ivanov, ...
European urology 75 (6), 940-947, 2019
762019
Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study
JSY Wu, G Monk, T Clark, J Robinson, BJC Eigl, N Hagen
Clinical oncology 18 (7), 539-544, 2006
722006
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
BJ Eigl, S North, E Winquist, D Finch, L Wood, SS Sridhar, J Powers, ...
Investigational new drugs 33, 969-976, 2015
622015
The system can't perform the operation now. Try again later.
Articles 1–20